EUVIMEDEUVIMED entdecken
KommentarOpen Access · CC BY-NC-SA 4.0

The efficacy of anti–TNF-α agents in the treatment of juvenile idiopathic arthritis-associated uveitis in a pediatric cohort

Mai Nasser Abd ElMohsen, Lameece Moustafa Hassan, Maha Mohamed Youssef, Shereen H Aboul Naga

Indian Journal of Ophthalmology · 2023

DOI: 10.4103/ijo.ijo_2548_22 ↗

Kurz gefasst

Kommentar in der Zeitschrift Indian Journal of Ophthalmology, 2023. Verfasst von Mai Nasser Abd ElMohsen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Faculty of Medicine, Kasr Al Ainy School of Medicine, Cairo University, Cairo, Egypt. Hauptthemen laut MEDLINE: Arthritis, Juvenile, Uveitis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Biologic therapy has shown promising control in children with often intractable juvenile idiopathic arthritis (JIA)-associated uveitis (JIA-U).

Methods

This is a retrospective cohort study of 35 eyes of 35 children who received biologics for JIA-U. Pretreatment and posttreatment data (at 3, 6, 9, 12, 18, 24, and >24 months) were analyzed to determine functional success (stable/improved visual acuity), quiescence success (≤0.5 cells in the anterior chamber), complete steroid success (termination of systemic, periocular therapy and decreased topical drops to ≤2/day) or systemic steroid success (termination of systemic steroids only), and complete success (all of the above).

Results

This study included 35 eyes up to 12 months and 21 eyes beyond 24 months. Steroid-sparing, functional, and quiescence success showed a rate of success of 52.43%, 77%, and 91%, respectively, at 12 months and 66.67%, 85.7%, and 76.2%, respectively, beyond 24 months. Complete success was 34.29% at 12 months, peaking at 18 months (65.62%) and reached 57.14% beyond 24 months. In their final follow-up, the best corrected visual acuity (BCVA) remained the same in 45.71%, improved in 37.14%, and worsened in 17.14% children.

Conclusion

Biologic therapy is effective in JIA-U, especially in termination of systemic steroids, stabilization of vision, and maintaining quiescence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, JuvenileUveitisChildHumansTumor Necrosis Factor-alphaAdalimumabTumor Necrosis Factor InhibitorsRetrospective Studies

Stichwörter der Autor:innen

AdalimumabJIA-Ubiologicsetanerceptimmunosuppressive therapyinfliximabpediatricsuveitis

Substanzen

Tumor Necrosis Factor-alphaAdalimumabTumor Necrosis Factor Inhibitors

Autor:innen und Institutionen

  • Department of Ophthalmology, Faculty of Medicine, Kasr Al Ainy School of Medicine, Cairo University, Cairo, Egypt.

Zitieren

APA

ElMohsen, M. N. A., Hassan, L. M., Youssef, M. M., & Naga, S. H. A. (2023). The efficacy of anti–TNF-α agents in the treatment of juvenile idiopathic arthritis-associated uveitis in a pediatric cohort. Indian Journal of Ophthalmology. https://doi.org/10.4103/ijo.ijo_2548_22

Vancouver

ElMohsen MNA, Hassan LM, Youssef MM, Naga SHA. The efficacy of anti–TNF-α agents in the treatment of juvenile idiopathic arthritis-associated uveitis in a pediatric cohort. Indian Journal of Ophthalmology. 2023. doi:10.4103/ijo.ijo_2548_22

BibTeX
@article{ElMohsen2023,
  author = {ElMohsen, Mai Nasser Abd and Hassan, Lameece Moustafa and Youssef, Maha Mohamed and Naga, Shereen H Aboul},
  title = {The efficacy of anti–TNF-α agents in the treatment of juvenile idiopathic arthritis-associated uveitis in a pediatric cohort},
  journal = {Indian Journal of Ophthalmology},
  year = {2023},
  doi = {10.4103/ijo.ijo_2548_22}
}
Kostenlos starten →